Combination immunotherapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a combination of two investigational drugs (IMM2510 and IMM01) that work with your immune system to fight cancer. It may help people with advanced solid tumors who have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of an advanced solid tumor (a cancer that forms in solid organs or tissues).
- You must be in good physical condition (able to do light activities).
- You must not have had another type of cancer in the past 5 years (except for certain skin or cervical cancers).
- You must not have active, symptomatic brain metastases or leptomeningeal disease (cancer spread to the brain or its lining).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.